Amarin Corp Plcuk (AMRN) Accumulated Depreciation & Amortization (2010 - 2025)
Amarin Corp Plcuk (AMRN) reported Accumulated Depreciation & Amortization of $1.5 million for Q4 2025, little changed year-over-year from $1.5 million in Q4 2024, and little changed quarter-over-quarter from $1.5 million in Q4 2024.
Amarin Corp Plcuk (AMRN) Accumulated Depreciation & Amortization (2010 - 2025) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 16 years of Accumulated Depreciation & Amortization data on file, last reported at $1.5 million in Q4 2025.
- Accumulated Depreciation & Amortization for Q4 2025 came in at $1.5 million, changed 0.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (changed 0.27% YoY), and the FY2025 annual result was $1.5 million, changed 0.27% from the prior year.
- Accumulated Depreciation & Amortization was little changed at $1.5 million in Q4 2025 per AMRN's latest filing, from $1.5 million in the prior quarter.
- Over five years, Accumulated Depreciation & Amortization peaked at $2.5 million in Q4 2022 and troughed at $1.4 million in Q4 2023.
- A 5-year average of $1.7 million and a median of $1.5 million in 2025 frame the typical range for Accumulated Depreciation & Amortization.
- The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation & Amortization climbed 28.68% in 2022, then sank 44.22% in 2023.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.9 million in 2021, then increased by 28.68% to $2.5 million in 2022, then slumped by 44.22% to $1.4 million in 2023, then advanced by 6.6% to $1.5 million in 2024, then advanced by 0.27% to $1.5 million in 2025.
- Business Quant data shows AMRN's Accumulated Depreciation & Amortization at $1.5 million in Q4 2025, $1.5 million in Q4 2024, and $1.4 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.47 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2022 | 2.47 Mn |
| Dec 31, 2022 | 2.47 Mn |
| Dec 31, 2021 | 1.92 Mn |
| Dec 31, 2021 | 1.92 Mn |
| Dec 31, 2020 | 1.62 Mn |
| Dec 31, 2020 | 1.62 Mn |
| Dec 31, 2019 | 1.02 Mn |
| Dec 31, 2019 | 1.02 Mn |
| Dec 31, 2018 | 839,000.00 |
| Dec 31, 2018 | 839,000.00 |
| Dec 31, 2017 | 816,000.00 |
| Dec 31, 2017 | 816,000.00 |
| Dec 31, 2016 | 743,000.00 |
| Dec 31, 2016 | 743,000.00 |